Track topics on Twitter Track topics that are important to you
Bayer will pay $400 million -- and up to $1.15 million more in milestones tied to regulatory approvals and sales -- for commercial rights to a rare cancer drug being developed by Loxo Oncology, a small Stamford, Conn.-based biotechnology firm.
Original Article: Loxo Sells Bayer Rights To Rare Cancer Drug For More Than $1 BillionNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...